West Pharmaceutical Services, Inc. WST reported third-quarter 2023 adjusted earnings per share (EPS) of $2.16, up 6.4% year over year. The figure beat the Zacks Consensus Estimate by 16.1%. The ...
West Pharmaceutical Services delivered a quarter that outperformed Wall Street’s expectations, reflecting renewed strength in its core high-value product (HVP) components. Management attributed the ...
The company raised full-year 2025 revenue guidance to a range of $3.04 billion to $3.06 billion (previously $2.945 billion to $2.975 billion), reflecting a positive foreign exchange impact now ...
9monon MSN
West Pharmaceutical targets 2-3% organic sales growth for 2025, highlights GLP-1 market expansion
Earnings Call Insights: West Pharmaceutical Services (NYSE:WST) Q4 2024 CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly ...
CEO Eric Green opened the call by noting solid third quarter results, with revenues, margins, and adjusted EPS coming in above expectations. Green stated, "Revenues of $805 million were up 5% on an ...
Campaigner, participatory development consultant and Chair of HVP Nepal-UK Currently leading a UK-wide campaign at The Woodland Trust, Matt is a campaigner with over 12 years of experience in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback